Nationwide Fund Advisors Aerie Pharmaceuticals Inc Transaction History

Nationwide Fund Advisors

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2017 Feb 01, 2018	SELL	$50.85 - $65.1 $3.64 Million - $4.66 Million	-71,609 Closed	0 $0
Q3 2017 Oct 23, 2017	BUY	$48.6 - $60.1 $504,565 - $623,958	10,382 Added 16.96%	71,609 $3.48 Million
Q2 2017 Aug 10, 2017	BUY	N/A	61,227	61,227 $3.22 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Nationwide Fund Advisors, based on Form 13F filings with the SEC.

Stay updated on Nationwide Fund Advisors with notifications on news.